Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Immunotherapy
What cancer immunotherapy is, how checkpoint inhibitors and monoclonal antibodies help the body recognise tumour cells, who qualifies for treatment, approximate cycle costs in Turkey compared with the UK, US and Germany, how infusions are given, what realistic outcomes look like, potential immune-related side effects, and how to verify an oncology hospital.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Immunotherapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is immunotherapy and how does it work against cancer?
Immunotherapy is an advanced biological cancer treatment that enables the human immune system to recognise, target, and eliminate malignant cells. While traditional cytotoxic interventions act directly against multiplying cells, immunotherapy works by altering the signalling between tumour cells and the body's immune defences, particularly cytotoxic T lymphocytes. Malignant tumours frequently evade immune destruction by expressing specific surface proteins—such as programmed death-ligand 1 (PD-L1)—that latch onto checkpoint receptors on immune cells and deactivate them. Immune checkpoint inhibitors block these signalling pathways, releasing the natural brakes of the immune system and allowing T cells to attack the malignancy.
In modern clinical oncology, immunotherapy includes immune checkpoint inhibitors, monoclonal antibodies, and cellular therapies. Hospitals in Turkey deliver these systemic biological therapies for a broad range of solid tumours and haematological conditions, either as single-agent protocols or combined with other modalities. This guide explains what is immunotherapy, how it works biologically, what the clinical evidence shows, approximate costs per cycle compared with the UK, US, and Germany, typical infusion routines, and essential patient safety guidelines. For an overview of wider systemic options, explore our guide to oncology treatments in Turkey.
Which types of cancer does immunotherapy treat?
Clinical indications for immunotherapy follow international guidelines published by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). Rather than applying universally to all malignancies, immune-based therapies are approved for specific tumour categories where clinical trials demonstrate clear therapeutic benefit.
Common clinical indications include advanced malignant melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, classic Hodgkin lymphoma, and head and neck squamous cell carcinomas. Tumours exhibiting high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)—found in subsets of colorectal and endometrial cancers—respond particularly well to checkpoint blockade regardless of anatomical location. Conversely, tumours described as immunologically "cold", which lack immune cell infiltration or relevant molecular checkpoints, rarely respond to standard checkpoint blockade alone.
Does immunotherapy actually work and what does evidence show?
When evaluating does immunotherapy work, clinical evidence confirms meaningful benefits for appropriately selected patients, though it is not effective for every individual or every tumour type. In responsive patients, checkpoint inhibitors can produce durable disease control, with clinical registries recording remissions lasting multiple years after completing therapy. This long-term response pattern differs from traditional chemotherapy, where tumour progression frequently resumes shortly after treatment stops.
However, overall response rates across unselected solid tumours typically range between 15% and 40% when single-agent checkpoint inhibitors are prescribed. Response likelihood increases substantially when tumours demonstrate high PD-L1 expression, elevated tumour mutational burden, or MSI-H status. Because outcomes depend heavily on these genetic and molecular characteristics, credible oncology teams perform comprehensive biomarker profiling before recommending treatment. Responsible specialists do not make clinical promises or claim immunotherapy is a guaranteed cure.
Immunotherapy cost in Turkey compared with the UK, US and Germany
The figures below reflect approximate cost ranges per single infusion cycle, rather than fixed hospital quotes. Systemic cancer therapies require recurring cycles administered every two to six weeks, meaning total investment depends on the overall duration of the treatment course. Accredited hospitals provide itemised written proposals following review of medical records and tumour pathology.
| Country | Approximate cost per cycle |
|---|---|
| Turkey | €2,000 – €5,500 |
| United Kingdom | €4,500 – €10,000 |
| United States | €7,000 – €16,000 |
| Germany | €4,000 – €9,500 |
Several clinical variables influence the immunotherapy price. The primary cost factor is the specific pharmaceutical molecule (such as pembrolizumab, nivolumab, ipilimumab, or atezolizumab), alongside patient body weight or fixed-dose requirements. Additional factors include mandatory pre-infusion biochemistry panels, day-case infusion suite fees, and specialist oncologist consultations. International oncology packages in Turkey typically bundle the medication, clinical administration, day bed, routine monitoring bloods, and airport transfers, providing clear immunotherapy cost transparency per cycle.
Immunotherapy, chemotherapy, targeted therapy or CAR-T cell therapy?
Selecting an appropriate oncology pathway requires understanding how immunotherapy compares with other systemic treatments. While standard cytotoxic chemotherapy attacks all rapidly dividing cells, immunotherapy engages the body's immune system to recognise cancer. Meanwhile, targeted therapy interferes with specific mutated oncogenic driver proteins, and cellular therapies such as car t cell therapy genetically reprogram autologous T cells.
| Method | Primary mechanism | Best suited to | Typical limits |
|---|---|---|---|
| Immunotherapy | Releases immune checkpoints to restore T-cell targeting | Biomarker-positive solid tumours, melanoma, lung and kidney cancers | Variable response rates; risk of autoimmune inflammatory reactions |
| Chemotherapy | Disrupts cell division directly across multiplying cells | Rapidly growing solid tumours and haematological malignancies | Systemic toxicity affecting healthy dividing tissues (hair, gut, bone marrow) |
| Targeted therapy | Inhibits specific mutated intracellular pathways (e.g. EGFR, ALK, BRAF) | Tumours carrying identifiable actionable genetic mutations | Tumour adaptation and development of secondary drug resistance |
| CAR-T cell therapy | Genetically engineers autologous T cells with chimeric antigen receptors | Refractory or relapsed leukaemia and lymphoma | Complex cell manufacturing process; potential cytokine release complications |
These modalities are often combined in modern oncological practice. Medical oncologists frequently pair checkpoint inhibitors with platinum-based chemotherapy or anti-angiogenic targeted agents to enhance tumour vulnerability.
Who is an eligible candidate for cancer immunotherapy?
Good candidates have a histologically verified malignancy known to respond to checkpoint blockade, substantiated by predictive biomarkers such as elevated PD-L1 expression, dMMR, or high tumour mutational burden. Candidates should also maintain reasonable functional independence, usually an ECOG performance status score of 0 or 1, alongside adequate kidney, liver, and haematological reserve.
Patients are less suited if they have severe active autoimmune disorders—such as uncontrolled lupus, Crohn's disease, or ulcerative colitis—where immune stimulation can precipitate dangerous inflammatory flares. High-dose systemic corticosteroids or other immunosuppressive medications also reduce treatment efficacy by dampening intended T-cell activation. Severe pre-existing organ failure or pregnancy also excludes patients from commencing treatment.
How is an immunotherapy infusion administered step by step?
Immunotherapy is administered in an outpatient day-care infusion suite under the direct supervision of a medical oncologist and oncology nurses. The clinical routine follows five structured steps.
First, the patient completes blood tests on the morning of treatment to confirm renal, hepatic, and haematological safety. Second, the medical oncologist reviews the laboratory findings and examines the patient. Third, vascular access is established via a peripheral cannula or an existing port. Fourth, mild premedications such as antihistamines are given if the specific protocol carries an infusion-reaction risk. Fifth, the medication is infused through an intravenous pump over 30 to 90 minutes. After a 30- to 60-minute monitoring period to confirm stability, the patient is discharged with comprehensive emergency contact guidelines.
Immunotherapy before and after: evaluating scans and tumour response
Unlike surgical procedures where visual changes are immediate, immunotherapy before and after progress is evaluated through objective radiographic imaging and tumour markers. Imaging studies—predominantly contrast-enhanced CT, MRI, or PET-CT—are typically scheduled every eight to twelve weeks to evaluate tumour dimensions.
Oncologists apply immune Response Evaluation Criteria in Solid Tumours (iRECIST) to interpret findings. A recognised phenomenon is pseudoprogression, in which an initial follow-up scan appears to show tumour enlargement or new lesions caused by an influx of activated immune cells infiltrating the tumour rather than true cancer growth. Subsequent scans often reveal tumour regression or durable disease stabilisation. Long-term disease stabilisation represents a significant clinical outcome that preserves daily function and quality of life.
Treatment schedules, travelling to Turkey and recovery between cycles
Planning immunotherapy Turkey travel requires coordinating international flights with structured cycle intervals. Checkpoint inhibitors are administered every two, three, four, or six weeks depending on the prescribed molecule. International patients typically spend three to five nights in Turkey per cycle, which provides adequate time for pre-treatment blood draws, specialist consultation, infusion delivery, and a post-treatment rest interval prior to air travel.
Daily immunotherapy recovery between cycles is generally less physically demanding than recovery from aggressive cytotoxic chemotherapy. Most patients avoid hair loss and severe nausea, continuing light daily activities and gentle walking. Managing recovery involves monitoring for signs of autoimmune inflammation, maintaining good hydration, and completing routine blood tests between visits. Many patients arrange interval blood tests with a medical practitioner at home while returning to Turkey for their scheduled infusions.
How to choose an oncology centre in Turkey and questions to ask
When selecting a hospital for immunotherapy in Turkey, patients should verify that the facility is licensed by the Turkish Ministry of Health and accredited by Joint Commission International (JCI). The treatment plan must be directed by a certified medical oncologist and reviewed within a multidisciplinary tumour board, where medical oncologists, surgical oncologists, radiation oncologists, radiologists, and pathologists collaborate on clinical recommendations.
The facility must feature an accredited intensive care unit, emergency facilities, and established protocols for managing acute immune toxicities. Red flags include promises of a guaranteed cure, quotes that omit the drug name and dosage, facilities without emergency departments, and pressure to commit without comprehensive pathology review. To see how international patient journeys are organised, review how it works. Patients can submit their diagnostic scans and pathology reports through our free quote portal to receive an expert medical assessment.
Key questions to ask the oncology team include:
- Has my tumour tissue undergone complete biomarker testing (such as PD-L1 expression or MSI status) to confirm indication?
- Will my therapeutic strategy be formally reviewed and approved by a multidisciplinary tumour board?
- What is the precise drug name, dosage in milligrams, and cycle schedule of the recommended immunotherapy?
- What emergency protocols and specialist teams are on site to manage immune-related adverse events?
- What comprehensive English-language medical documentation and imaging records will I receive to share with my local oncologist at home?
Hospitals with Oncology in Turkey
Frequently asked questions
Immunotherapy is a specialised cancer treatment that helps your immune system identify and destroy cancer cells. While traditional treatments attack tumours directly, immunotherapy uses medications such as checkpoint inhibitors to disable the protective chemical signals that cancer cells use to hide from T cells, allowing your natural defences to fight the disease.
Clinical trials and real-world oncology data show that immunotherapy can produce durable responses, with some patients achieving long-term remission. However, effectiveness varies widely depending on tumour type, stage, and biological markers like PD-L1 expression. It does not work for every patient or all cancer types, which is why prior biomarker testing is essential.
In Turkey, an immunotherapy infusion typically ranges from €2,000 to €5,500 per cycle, compared with €4,500 to €10,000 in the UK and up to €16,000 in the US. The total cost depends on the specific drug, required dosage based on body weight, cycle frequency, and necessary laboratory monitoring.
Before-and-after evaluations rely on CT, MRI, or PET scans rather than physical changes. Scans taken every two to three months assess tumour shrinkage or stability. In some cases, initial scans show temporary tumour enlargement—known as pseudoprogression—caused by immune cells infiltrating the tumour, which settles on follow-up imaging.
Chemotherapy uses cytotoxic chemicals to destroy rapidly dividing cells directly throughout the body, frequently causing systemic side effects like hair loss and severe nausea. Immunotherapy works indirectly by training or releasing the immune system to attack cancer cells. It often has fewer general side effects, though it can trigger unique autoimmune inflammatory reactions.
Recovery between cycles is generally smoother than with traditional chemotherapy. Most patients experience mild fatigue or skin dryness but can maintain normal daily activities. Recovery involves staying well-hydrated, monitoring for signs of autoimmune inflammation such as unexpected diarrhoea or shortness of breath, and attending scheduled blood tests before each subsequent infusion.
The infusion itself is not painful. It is administered through an intravenous drip or an existing port in an outpatient day clinic, similar to receiving a standard saline solution. Patients may feel a minor pinch during needle insertion. Mild sensations during the infusion, such as warmth or temporary fatigue, are managed with routine supportive care.
Treatment duration depends on the cancer type, clinical protocol, and tumour response. Many patients receive infusions every two to six weeks for up to one to two years, provided the tumour remains controlled and side effects are manageable. Treatment is discontinued if the cancer progresses or if severe immune toxicities arise.
Immunotherapy is widely used under strict oncological supervision, but it carries distinct risks termed immune-related adverse events. When the immune system is activated, it can occasionally target healthy tissues, causing inflammation of the colon, lungs, liver, or endocrine glands. Early reporting of symptoms allows oncologists to treat these reactions effectively with corticosteroids.
Most international patients stay in Turkey for three to five days per treatment cycle. This schedule allows sufficient time for baseline blood tests and oncologist consultations before the infusion, the day-care infusion itself, and a 24- to 48-hour post-treatment observation window before safe travel home.
Patient stories